ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2026
Improving syndromic testing in oncology: performance characteristics of multiplex PCR assays for evaluation of infectious gastroenteritis among hospitalized cancer patients.
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Multiplex gastrointestinal polymerase chain reaction (GI-PCR) tests of the stool for the evaluation of infectious diarrhea are prone to false-positive target detections. However, there is no recommended testing approach in immunocompromised cancer patients who are often excluded from diagnostic stewardship protocols. The aim of this study was to evaluate the performance characteristics of the BioFire® FilmArray® GI-PCR and assess whether the findings support a diagnostic stewardship approach to limit testing among hospitalized cancer patients. Methods: A retrospective study of 29,727 GI-PCR tests was performed at Memorial Sloan Kettering Cancer Center in New York City, evaluating data from February 1, 2020, to January 29, 2025. All tests sent from all locations and across all patient types were included in the study. Results: The overall GI-PCR positivity rate was greatest in the outpatient setting at 23.4% and dropped at 15.6% in the early stage of admission (hospital days 0-2) and 10.1% in the late stage of admission (hospital day 3 and beyond). Across all subgroups analyzed, norovirus and Enteropathogenic Conclusion: BioFire FilmArray GI panel has low utility in the inpatient setting including for severely immunosuppressed hosts. These observations identify a potential opportunity for diagnostic stewardship and suggest that commonly applied testing restrictions may warrant further evaluation in immunocompromised oncology populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.